Revenue
2013
2014
2015
2016
2017
2018
2019
2022
2023
2024
2025
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | $1.6M | $1.7M | $3.4M | $3.0M | $2.1M | $4.4M | $3.6M |
| Gross profit | $0 | $0 | $0 | $0 | — | — | $478,747 | $127,285 | $948,580 | $1.9M | $1.2M | $3.3M | $1.7M |
| Gross margin | — | — | — | — | — | — | 30.36% | 7.64% | 28.28% | 63.42% | 55.05% | 73.45% | 46.51% |
| Research & development | $3.5M | $3.4M | $7.9M | $9.1M | $6.7M | $2.5M | $276,788 | $1.1M | $1.3M | $1.2M | $1.4M | $916,308 | $1.0M |
| Operating expenses | $9.6M | $8.7M | $16.4M | $15.3M | — | — | $4.0M | $10.2M | $7.6M | $5.2M | $10.8M | $6.5M | $3.5M |
| Operating income | −$9.8M | −$10.2M | −$17.1M | −$15.3M | −$28.8M | −$9.5M | −$3.5M | −$10.1M | −$6.6M | −$3.3M | −$9.7M | −$3.2M | −$1.8M |
| Operating margin | — | — | — | — | — | — | −220.17% | −604.02% | −197.15% | −112.42% | −457.78% | −72.37% | −50.61% |
| EBITDA | −$9.6M | −$8.7M | −$16.4M | −$15.3M | — | −$9.5M | −$3.4M | −$9.8M | −$6.4M | −$3.0M | −$9.4M | −$2.9M | −$1.5M |
| EBITDA margin | — | — | — | — | — | — | −215.47% | −589.94% | −189.70% | −102.75% | −443.59% | −64.48% | −40.70% |
| Net income | −$11.6M | −$23.4M | −$4.0M | −$15.2M | −$29.9M | −$9.5M | −$3.9M | −$10.8M | −$7.4M | −$3.3M | −$9.3M | −$3.1M | −$1.5M |
| Net profit margin | — | — | — | — | — | — | −246.55% | −651.37% | −219.58% | −111.57% | −440.27% | −70.99% | −42.67% |
| Basic EPSper basic share | -$8.66 | -$1,092.70 | -$522.34 | -$1,150.52 | -$2,499.00 | -$14,641.20 | -$37,338.00 | -$131,006.40 | -$850,659.60 | -$659,971.20 | -$1,958,275.20 | -$714,067.20 | -$1,038,643.20 |
| Diluted EPSper diluted share | -$8.66 | -$1,092.70 | -$522.34 | -$1,150.52 | — | -$14,641.20 | -$37,338.00 | -$131,006.40 | -$850,659.60 | -$659,971.20 | -$1,958,275.20 | -$714,067.20 | -$1,038,643.20 |
Reported shareholders
| Holder | % owned |
|---|---|
Voss Chelsea Sierra | ≈3.68%301.46K shares |
Silverman Joshua | ≈3.20%262.19K shares |
Quinn Opportunity Partners LLC | 1.50%123.02K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 1.40%115.03K shares |
JANE STREET GROUP, LLC | 1.07%87.24K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.86%70.68K shares |
UBS Group AG | 0.72%58.89K shares |
Balyasny Asset Management L.P. | 0.70%57.69K shares |
HRT FINANCIAL LP | 0.62%50.37K shares |
ADAR1 Capital Management, LLC | 0.61%50K shares |
VANGUARD FIDUCIARY TRUST CO | 0.53%43.05K shares |
STATE STREET CORP | 0.31%25.31K shares |
White Billy Joe | ≈0.31%25.02K shares |
Bernstein Bruce | ≈0.31%25K shares |
Friscia Stephen | ≈0.31%25K shares |
DIMENSIONAL FUND ADVISORS LP | 0.23%19.06K shares |
NORTHERN TRUST CORP | 0.22%18K shares |
PEAK6 LLC | 0.16%12.78K shares |
RAUCH GARY M | ≈0.15%12.5K shares |
Glass Mitchell | ≈0.15%12.5K shares |
Percentages use 8.19M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 30, 2026Form 4 | Voss Chelsea SierraDirector | BuyCommon stock · indirect | 1.8K | $3.15 | $5.5K | 61.6K |
| Nov 14, 2025Form 4 | PharmaCyte Biotech, Inc.TenPercentOwner | BuyWarrants · derivative | 889.9K | — | — | 889.9K |
| Sep 4, 2025Form 4 | PharmaCyte Biotech, Inc.TenPercentOwner | BuySeries H Convertible Preferred Stock · derivative | 889.9K | — | — | 889.9K |